We are live on ! Find out more
ACIU icon

AC Immune

41 hedge funds and large institutions have $90.6M invested in AC Immune in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 6

5% more funds holding

Funds holding: 39 → 41 (+2)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

3.52% less ownership

Funds ownership: 30.06% → 26.54% (-3.5%)

37% less capital inflows, than outflows

Capital inflows: $47M | Capital outflows: $74.2M

Holders
41
Holders Change
+2
Holders Change %
+5.13%
% of All Funds
0.88%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
15
Reduced
6
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ACIU Hedge Fund Activity: Q1 2019 in Review

41 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q1 2019, worth a combined $90.6M — down 53% from $191M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ACIU positions and 14 closed out — a net gain of 1 holder — while 15 added to existing stakes and 6 trimmed.

The largest buyer was BVF Inc, adding an estimated $33.2M. The largest seller was Fidelity Investments, cutting an estimated $22.4M.

  • 41 institutional investors held AC Immune (ACIU) as of Q1 2019, up from 39 in Q4 2018.
  • Funds reported $90.6M of AC Immune stock for Q1 2019, down 53% quarter-over-quarter.
  • 15 funds opened new AC Immune positions in Q1 2019 and 14 closed out, a net change of +1 holder.
  • The largest AC Immune buyer in Q1 2019 was BVF Inc, an estimated $33.2M added.
  • The largest AC Immune seller in Q1 2019 was Fidelity Investments, an estimated $22.4M sold.

Based on aggregated 13F filings for Q1 2019.